Psoriasis Treatment Guidelines

Introduction to Psoriasis Management

The American Academy of Dermatology recommends tailoring treatment for psoriasis based on disease severity, with topical therapies for mild disease, phototherapy for moderate disease, and systemic/biologic agents for severe disease or those with psoriatic arthritis 1, 2, 3
Psoriasis severity is categorized as mild (typically <5% body surface area [BSA]) or moderate-to-severe (≥5% BSA or involvement of vulnerable areas) 2, 3

Patients with symptomatic psoriasis (pain, bleeding, itching) should be considered for systemic or phototherapy even if BSA involvement is limited 3
Quality of life impact should be considered when selecting therapy, as psychological distress can be significant regardless of physical extent 1, 4

For mild psoriasis, first-line treatment includes topical therapies such as topical corticosteroids, vitamin D analogs, and combination products 1, 2, 3
For moderate-to-severe psoriasis, first-line treatment includes phototherapy, with options such as narrowband UVB and PUVA 1, 2
Second-line options for moderate-to-severe psoriasis include traditional systemic agents like methotrexate, cyclosporine, and acitretin 1, 2, 3
Third-line options for moderate-to-severe psoriasis include biologic agents like TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors 2, 3, 5

For scalp psoriasis, treatment options include calcipotriene foam or calcipotriene plus betamethasone dipropionate gel for 4-12 weeks 3
For facial and intertriginous psoriasis, low-potency corticosteroids are recommended to avoid skin atrophy 3
For psoriatic arthritis, treatment options include NSAIDs for mild joint symptoms, DMARDs for moderate-to-severe joint involvement, and TNF inhibitors for inadequate response to at least one DMARD 5

Combination therapy with topical corticosteroids plus vitamin D analogs enhances efficacy and reduces irritation 6
Rotational therapy (switching between treatment modalities every 1-2 years) may minimize cumulative toxicity of individual treatments

Systemic corticosteroids should be avoided in psoriasis as they can cause disease flare during taper 4
Long-term use of potent topical corticosteroids can cause skin atrophy, striae, and telangiectasia
Vitamin D analogs should be applied after phototherapy to avoid inactivation 3
Combination of multiple systemic agents may increase risk of toxicity 4

Oral curcumin supplementation may benefit as adjunctive therapy 6
Mindfulness meditation and stress reduction techniques can improve psoriasis severity in some patients 6
Gluten-free diet should only be considered for patients diagnosed with celiac disease 6

Coal tar, anthralin, and salicylic acid are other topical options with varying degrees of efficacy for patients with mild psoriasis, according to the British Medical Journal 7
Drugs that may precipitate or worsen psoriasis include alcohol, beta-blockers, NSAIDs, lithium, chloroquine, and mepacrine, as reported in the British Medical Journal 7
Guidelines for topical corticosteroid use include regular clinical review, no unsupervised repeat prescriptions, and periods of alternative treatment each year, as recommended by the British Medical Journal 7
Psoriasis is a chronic condition requiring long-term management, with treatment aiming to induce remission and make the condition tolerable for patients, as stated in the British Medical Journal 7

For patients with psoriatic arthritis, TNF inhibitors like adalimumab are effective for both skin and joint symptoms, according to the Annals of the Rheumatic Diseases 8